Ipsen’s Meek to helm Ferring’s gene therapy unit

David Meek will step down as CEO of Ipsen at year end to become president and CEO of Ferring’s newly formed gene therapy subsidiary, effective Jan. 14.

Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched FerGene in November with a combined $570 million to commercialize nadofaragene firadenovec in the U.S. This month, FerGene said the gene therapy met the primary endpoint in a Phase III trial to treat Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer (see “Bladder Cancer Data Poise FerGene gene therapy to compete with Keytruda”). ...